Uric acid reducing plant source composition

Through the compositions of celery seed extract, needle cherry extract and chrysanthemum extract, the side effects and limited results of uric acid reduction in the prior art are solved, safe and effective control of uric acid level and gout prevention are achieved, with significant Synergistic effect.

CN118903272APending Publication Date: 2024-11-08SHENZHEN FULAITE NUTRITION & HEALTH CO LTD +1
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310504923.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art has problems with side effects and limited effectiveness in reducing uric acid levels, especially for patients with hyperuricemia, where a safe and effective composition is needed to control uric acid levels over the long term and prevent gout attacks.

Method used

The composition of celery seed extract, needle cherry extract and chrysanthemum extract is used to adjust the dosage ratio and act on the uric acid formation and excretion mechanism to form a safe and effective oral dosage form to reduce uric acid levels.

Benefits of technology

It significantly reduces uric acid levels, promotes uric acid excretion, reduces xanthine oxidase activity, relieves inflammation and peroxidation, has the effect of preventing gout attacks and treating gout, and is safe and without side effects, and has the function of preventing cardiovascular diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_2
    Figure SMS_2
Patent Text Reader

Abstract

The invention discloses a composition with an effect of reducing uric acid. The composition is prepared from a celery seed extract, an acerola cherry extract, a chrysanthemum extract and a proper amount of auxiliary materials. The traditional Chinese medicine composition has the advantages that plant extracts with exact functions are carefully selected and scientifically formulated, and all the components of the composition have a synergistic effect in the aspects of reducing the uric acid level and treating and preventing hyperuricemia or gout; in addition, the compound form adopted by the invention is also beneficial to improving the taking compliance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a composition containing celery seed extract, acerola cherry extract and chrysanthemum extract, which is used for preventing and reducing uric acid level. The invention belongs to the field of health. Background Art

[0002] The "White Paper on Hyperuricemia and Gout Trends in 2021" shows that hyperuricemia in my country is showing a clear upward and younger trend. Hyperuricemia refers to the fasting blood uric acid level of two different days in a normal purine diet state, which is higher than 420μmol / L for men and higher than 360μmol / L for women. Uric acid is the final product of purine metabolism in the human body. Excessive production or insufficient excretion will lead to increased uric acid in the blood. When the concentration of uric acid in the blood exceeds the ability of the blood to dissolve urate, urate will crystallize and precipitate from the blood, and deposit in joints, soft tissues, cartilage, kidneys and other parts. The urate deposited in the joints causes an inflammatory reaction in the joints, resulting in gout-related symptoms such as severe pain, redness and swelling.

[0003] In vivo, xanthine oxidase is the key enzyme that decomposes purine into uric acid. Currently, drugs that reduce uric acid mainly include allopurinol and febuxostat that inhibit xanthine oxidase and benzbromarone that promotes diuresis and excretion. Studies have shown that the source of purine is self-metabolism (endogenous purine, 80%, uncontrollable factors) and food intake (exogenous, 20%, controllable factors), and the blood uric acid content increases with age. Endogenous purines are mostly adenine and guanine released after DNA damage, which are then converted into xanthine by xanthine oxidase and then converted into uric acid. The above three gout treatment drugs all have side effects to varying degrees, especially benzbromarone has been banned or withdrawn from the market in some European countries. Although controlling diet can reduce the generation of uric acid, it is easy to rebound and has limited effect. Therefore, the development of a composition that can effectively reduce uric acid has become a problem that urgently needs to be solved. This can not only ensure the quality of life of patients for a long time, but also reduce the risk of diseases related to hyperuricemia.

[0004] Celery seed extract is an extract of the mature seeds of the Umbelliferae plants water celery and celery. It contains volatile oils, apigenin, bergamot lactone, organic acids and other substances, and has a significant effect on reducing uric acid, with high doses being the best (Effects of celery seed extract on blood uric acid and antioxidant capacity in hyperuricemia model rats, Medical Information, 2018, 31(13), 84-87). Acerola is the Chinese name for Acerola cherry. Acerola cherry is rich in vitamin C and is the fruit with the richest vitamin C content in the world. Acerola cherry also contains vitamin A, B1, B2, E, P, nicotinic acid, anti-aging factor (SOD), calcium, iron, zinc, potassium and protein and other nutrients. Pharmacological studies have found that acerola cherry extract can improve animal immunity (Study on the effect of acerola cherry extract tablets on enhancing immunity in mice, Journal of Preventive Medicine Intelligence. 2015, 31(07)). Dong Weixue disclosed that the six flavonoids in cherries can directly reduce uric acid levels, and can also relieve the body's peroxidation and inflammation caused by high uric acid, and have a good effect on treating hyperuricemia (Study on Cherry Flavonoid Components and Uric Acid-Lowering Effects, Shaanxi University of Science and Technology, Issue 10, 2020). Chrysanthemum extract is an extract of the dried inflorescence of the chrysanthemum plant of the Asteraceae family, which has the effects of dispersing wind and clearing heat, calming the liver and improving eyesight. Peng An disclosed that Boju extract can reduce the production of uric acid by reducing the activity of serum xanthine oxidase (XO), upregulating the expression of ABCG2 in rat kidneys, downregulating the expression of GLUT9 and URAT1 to promote uric acid excretion, protect kidney function, improve dyslipidemia, and reduce serum uric acid levels (Study on the mechanism of action of Boju extract in improving hyperuricemia in rats and its XOI activity spectrum-effect relationship, South China University of Technology, Issue 02, 2021). Summary of the invention

[0005] The object of the present invention is to provide a safe and effective composition for reducing uric acid. The composition acts on the pre-formation stage, the formation stage and promotes the degradation of uric acid based on various mechanisms of uric acid formation.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] A safe and effective composition for reducing uric acid levels, comprising the following ingredients:

[0008] (1) an effective amount of celery seed extract;

[0009] (2) an effective amount of acerola cherry extract;

[0010] (3) an effective amount of chrysanthemum extract;

[0011] Among them, the dosage ratio of celery seed extract, acerola cherry extract and chrysanthemum extract is 10-50:1-5:1-5.

[0012] In the present invention, the weight proportion of the celery seed extract in the composition is 200-1000 parts, the weight proportion of the acerola cherry extract is 20-100 parts, and the weight proportion of the chrysanthemum extract is 20-100 parts. Preferably, the weight proportion of the celery seed extract is 250-1000 parts, the weight proportion of the acerola cherry extract is 24-96 parts, and the weight proportion of the chrysanthemum extract is 25-100 parts.

[0013] In a preferred embodiment of the present invention, the weight proportion of the celery seed extract is 250 parts, the weight proportion of the acerola cherry extract is 24 parts, and the weight proportion of the chrysanthemum extract is 25 parts.

[0014] In a preferred embodiment of the present invention, the weight proportion of the celery seed extract is 500 parts, the weight proportion of the acerola cherry extract is 24 parts, and the weight proportion of the chrysanthemum extract is 25 parts.

[0015] In a preferred embodiment of the present invention, the weight proportion of the celery seed extract is 500 parts, the weight proportion of the acerola cherry extract is 48 parts, and the weight proportion of the chrysanthemum extract is 50 parts.

[0016] In a preferred embodiment of the present invention, the weight proportion of the celery seed extract is 750 parts, the weight proportion of the acerola cherry extract is 72 parts, and the weight proportion of the chrysanthemum extract is 75 parts.

[0017] In a preferred embodiment of the present invention, the weight proportion of the celery seed extract is 1000 parts, the weight proportion of the acerola cherry extract is 96 parts, and the weight proportion of the chrysanthemum extract is 100 parts.

[0018] The composition of the present invention can be prepared into oral dosage forms such as common tablets, chewable tablets, soft capsules, hard capsules, powders, granules, solid beverages, etc. by adding auxiliary materials.

[0019] In the present invention, the auxiliary materials are selected from one or a combination of fillers (dispersants), suspending agents, wetting agents, adhesives, disintegrants, lubricants, flavoring agents, stabilizers, embedding materials, coating premixes, and food colorings.

[0020] Among them, the filler (dispersant) described in the present invention includes one or more of starch, soluble starch, dextrin, maltodextrin, potato starch, corn starch, wheat starch, D-mannitol, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, maltose, xylitol, sorbitol, microcrystalline cellulose, isomaltulose, milk powder, low-substituted hydroxypropyl cellulose, sucrose, glucose, lactose, pregelatinized starch, edible vegetable oil, polyethylene glycol, etc.

[0021] The suspending agent of the present invention includes one or more of beeswax, insect wax, lecithin, glyceryl monostearate, ethyl cellulose, etc., the wetting agent includes purified water and ethanol, and the binder includes one or more of hydroxypropyl methylcellulose, povidone, hydroxypropyl cellulose, sodium carboxymethyl cellulose, starch, methyl cellulose, ethyl cellulose, gelatin, polyethylene glycol, pregelatinized starch, sucrose, glucose, etc.

[0022] The disintegrant of the present invention includes one or more of starch, sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, sodium bicarbonate and citric acid, and the lubricant includes one or more of magnesium stearate, stearic acid, talc, silicon dioxide, hydrogenated vegetable oil, polyethylene glycol, sodium lauryl sulfate, glyceryl behenate, sodium stearyl fumarate, etc.

[0023] The flavor corrector of the present invention comprises one or more of fruit powder, edible flavor, high-intensity sweetener, acidulant and the like; the fruit powder comprises one or more of orange powder, lemon powder, cherry powder, apple powder, strawberry powder, strawberry powder, kiwi fruit powder, tangerine powder, sea buckthorn fruit powder, green plum fruit powder, mango fruit powder, mulberry fruit powder, hawthorn fruit powder, watermelon fruit powder, pineapple fruit powder, blueberry fruit powder, peach fruit powder, cantaloupe fruit powder, grape fruit powder, vanilla fruit powder, pomegranate fruit powder, rose fruit powder and the like.

[0024] The edible flavors described in the present invention include vanilla flavor, sweet orange flavor, milk flavor, apple flavor, grape flavor, strawberry flavor, pineapple flavor, peach flavor, cantaloupe flavor, lemon flavor, cherry flavor, sweet corn flavor, banana flavor, raisin flavor, grape flavor, rose flavor, blackcurrant flavor, green apple flavor, mango flavor, green mango flavor, orange flavor, orange flavor, snow pear flavor, strawberry flavor, green plum flavor, blueberry flavor, bayberry flavor, grapefruit flavor, pineapple flavor, guava flavor, passion fruit flavor, kiwi flavor, cherry flavor, kiwi flavor, watermelon flavor, papaya flavor, cantaloupe flavor, durian flavor, lychee flavor, hawthorn flavor, olive flavor, mulberry flavor, etc.

[0025] The high-intensity sweeteners described in the present invention include sucralose, aspartame, mogroside, neotame, and stevioside. The acidulants include citric acid, citric acid, malic acid, lactic acid, tartaric acid, and fumaric acid. The food pigments include one or more of caramel color, gardenia yellow, curcumin and chlorophyll, capsicum orange, capsicum red, grape skin red, carmine and its aluminum lake, sunset yellow and its aluminum lake, brilliant blue and its aluminum lake, indigo and its aluminum lake, beetroot red, natural amaranth, gardenia blue, plant carbon black, black iron oxide, red iron oxide, black bean red, quinoline yellow, lycopene, red monascus, yellow iron oxide, cocoa shell color, safflower yellow, and monascus yellow pigment.

[0026] The stabilizer described in the present invention includes vitamin E, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), and vitamin C. The embedding material includes one or more of β-cyclodextrin, α-cyclodextrin, γ-cyclodextrin, dextrin, starch, edible modified starch, sucrose, maltodextrin, gum arabic, and the like.

[0027] The present invention also provides the use of the above composition in preparing products capable of reducing uric acid. The above products are not limited to food, health products, health food, functional food, medicine and the like.

[0028] The present invention also provides a method for preparing the above composition, the steps comprising:

[0029] 1. Mix celery seed extract, acerola cherry extract and chrysanthemum extract for 5 minutes, and pass the mixture through a 50-mesh sieve to obtain mixture I.

[0030] 2. Mix mixture I and other auxiliary materials for 10 minutes to obtain mixture II.

[0031] 3. Add magnesium stearate and obtain the total mixed powder after mixing.

[0032] The present invention screens celery seed extract, acerola cherry extract and chrysanthemum extract with synergistic functions for scientific formulation. By selecting the optimal dosage or dosage ratio of the composition components, it not only significantly synergistically reduces the uric acid level, but also promotes uric acid excretion, which is beneficial for the rapid control of the uric acid level of patients with hyperuricemia, thereby preventing gout attacks, relieving pain and treating gout. Compared with existing products, the present invention is a safer and more effective composition product, and its effect is also significantly stronger than the single application effect of the components, and it has an unexpected synergistic effect in reducing uric acid. It can be used for daily health care of patients with hyperuricemia, is safe and has no side effects, and also has the function of assisting in the prevention of cardiovascular diseases.

[0033] The embodiments of the present invention are further described below in conjunction with examples. DETAILED DESCRIPTION

[0034] Example 1: Preparation method of the composition tablet of the present invention

[0035] 1. Raw material composition: 250g celery seed extract, 24g acerola powder, 25g chrysanthemum extract.

[0036] 2. The auxiliary materials are: 545g isomalt and 10g magnesium stearate.

[0037] 3. Preparation method: (1) Determine the moisture content of each raw material and control the moisture content to ≤5.0%; (2) Weigh each raw material according to the formula; (3) Mix celery seed extract, acerola cherry powder and chrysanthemum extract for 5 minutes, pass through a 50-mesh sieve, add isomalt and mix for 20 minutes, then add magnesium stearate and mix for 5 minutes, put the materials into a turnover container and weigh them, take samples and test the moisture content on a moisture meter, and control the moisture content of the above materials to ≤5.0%; (4) Compress the material obtained in step (3) into 1000 tablets using a tablet press, control the hardness to be between 12 and 20 kg, and control the tablet weight to be within the range of 1.0 g ± 4%.

[0038] Example 2: Preparation method of the composition tablet of the present invention

[0039] 1. Raw material composition: 1000g celery seed extract, 96g acerola powder, 100g chrysanthemum extract.

[0040] 2. The auxiliary materials are: 794g isomalt and 10g magnesium stearate.

[0041] 3. Preparation method: (1) Determine the moisture content of each raw material and control the moisture content to ≤5.0%; (2) Weigh each raw material according to the formula; (3) Mix celery seed extract, acerola powder and chrysanthemum extract for 5 minutes, pass through a 50-mesh sieve, add isomalt and mix for 10 minutes, then add magnesium stearate and mix for 5 minutes, put the materials into a turnover container and weigh them, take samples and test the moisture content on a moisture meter, and control the moisture content of the above materials to ≤5.0%; (4) Compress the material obtained in step (3) into 1000 tablets using a tablet press, control the hardness to 12-20 kg, and control the tablet weight to 2.0 g ± 4%.

[0042] Example 3: Effect of the composition of the present invention on uric acid in mice

[0043] SPF grade Kunming mice, male, 20-22g. After 5 days of animal adaptation, 10 mice were taken as the blank control group, and the rest of the animals were gavaged with hypoxanthine (250 mg / kg) and potassium oxonate (300 mg / kg) suspension every day for 7 consecutive days. After the model was successfully established, the drugs were gavaged as shown in Table 1. The blank control group and the model group were given the same amount of normal saline every day. The dosage of celery seed extract in celery seed group 1 was 35.7 mg / kg (corresponding to a human dosage of about 250 mg), the dosage of acerola cherry extract in cherry group 1 was 3.4 mg / kg (corresponding to a human dosage of about 24 mg), and the dosage of chrysanthemum extract in chrysanthemum group 1 was 3.6 mg / kg (corresponding to a human dosage of about 25 mg), and the rest was analogous. The dosage of celery seed extract + acerola cherry extract + chrysanthemum extract in composition group 1 was (35.7 + 3.4 + 3.6) mg / kg; the dosage of celery seed extract + acerola cherry extract + chrysanthemum extract in composition group 2 was (142.8 + 13.6 + 14.4) mg / kg; the dosage of celery seed extract + acerola cherry extract + chrysanthemum extract in composition group 3 was (142.8 + 54.4 + 57.6) mg / kg. For 20 consecutive days. After the last administration, fasting but not water restriction was performed for 24 hours, and the 24-hour urine of mice was collected in a mouse metabolic cage, and the UA in the collected urine was determined. The serum uric acid (UA) content was detected using a uric acid test kit (Nanjing Jiancheng Bioengineering Institute). After removing the eyeballs of the mice and drawing blood, the mice were killed, the abdominal cavity of the mice was opened, and the liver was quickly taken out. Part of the liver was weighed and mixed with physiological saline, homogenized and centrifuged, and the xanthine oxidase test kit (Nanjing Jiancheng Bioengineering Institute) and adenosine deaminase enzyme-linked immunosorbent assay (ELISA) kit (Suzhou Colvin Biotechnology Co., Ltd.) of mouse liver tissue homogenate in the supernatant were used to detect the activities of xanthine oxidase (XOD) and adenosine deaminase (ADA).

[0044] In order to verify the scientific nature of the pharmaceutical composition provided by the present invention, and to illustrate that the three components of the pharmaceutical composition are reasonably matched and can play a synergistic role in combination, rather than simply superimposing pharmacological effects, the Jin Zhengjun Q value method is introduced for analysis. The Jin Zhengjun Q value method is also known as the probability addition method. According to the pharmacological effects of the combination of two drugs and the pharmacological effects of the two drugs alone in the dose-effect curve area, the following calculation formula is used to calculate: Q = E A+B / (E A +E B -E A *E B ), where the numerator represents the "measured combined effect" and the denominator represents the "expected combined effect". (In order to analyze the pharmacological effects of components and combinations, their pharmacological effects are converted into effects that can intuitively reflect the strength of the pharmacological effects. The calculation formula is: E i =1-P i / P 模型组 , P iis the pharmacological index of each component, P 模型组 =E = pharmacological index of the model group), Q is the ratio of the two: when Q is less than 0.85, the combination of the two drugs is considered to be antagonistic; when it is less than 1.15 and greater than 0.85, it is considered to be additive; when it is greater than 1.15, it is considered to be synergistic. Based on the calculation formula for the combined use of two drugs, the pharmacological effects of the combination of three drugs and the pharmacological effects of the three drugs alone are calculated using the following formula: Q = E A+B+C / (E A +E B +E C -E A *E B -E A *E C -E B *E C -E A *E B *E C ).

[0045] SPSS 20.0 was used to analyze the data, and the measurement data were expressed as mean ± standard deviation and the t-test was used.

[0046] The experimental results showed that after hypoxanthine and potassium oxonate modeling, the uric acid level, XOD and ADA activity of the model group mice were significantly increased compared with the blank control group, indicating that the hyperuric acid mouse modeling was successful. Compared with the model group, there was no significant change in UA, XOD and ADA in the celery seed group 1, but the celery seed group 2 could significantly reduce the uric acid level, XOD and ADA activity, indicating that high-dose celery seed extract has a significant effect in reducing hyperuricemia. Compared with the model group, there was no significant change in UA, XOD and ADA in the cherry group 1, cherry group 2, cherry group 3, chrysanthemum group 1, chrysanthemum group 2, and chrysanthemum group 3, which is consistent with our previous research results that acerola cherry extract and chrysanthemum extract require a large amount to exert their effects. In the composition group 1, after the low dose of celery seed extract, acerola cherry extract and chrysanthemum extract were used together, the uric acid level, XOD and ADA activity were significantly decreased, which had a significant statistical difference compared with the model group; after the high dose of celery seed extract, higher dose of acerola cherry extract and chrysanthemum extract were used together in the composition group 2, the uric acid level, XOD and ADA activity were significantly decreased, which had a significant or very significant statistical difference compared with the model group; after the high dose of celery seed extract, high dose of acerola cherry extract and chrysanthemum extract were used together in the composition group 3, the uric acid level, XOD and ADA activity were significantly decreased, which was slightly stronger than the effect of the composition group 2, and had a very significant statistical difference compared with the model group.

[0047] The Q values ​​of the effects of composition group 1 and composition group 2 on uric acid levels, XOD and ADA activities with the corresponding celery seed extract, acerola cherry extract and chrysanthemum extract were all greater than 1.15, indicating that the acerola cherry extract and chrysanthemum extract within the dosage or dosage ratio range, when used alone, can not show an effect, and when used in combination with a specific dosage of celery seed extract, they can exert a significant synergistic uric acid-lowering effect that is stronger than the celery seed extract alone; the Q value of composition group 1 is greater than the Q value of composition group 2, indicating that the synergistic effect of the low dosage composition is stronger. The Q values ​​of the effects of composition group 3 and the corresponding celery seed extract, acerola cherry extract and chrysanthemum extract on uric acid levels, XOD and ADA activities are all less than 1.15, indicating that with the increase in the dosage of acerola cherry extract and chrysanthemum extract and the enhancement of the effect of lowering uric acid levels, the uric acid-lowering effect of the composition composed of acerola cherry extract, chrysanthemum extract and celery seed extract exceeding the scope of the present invention is no longer synergistic.

[0048] Table 1. Effects of the composition of the present invention on the activities of uric acid, xanthine oxidase and adenosine deaminase in mice (n=9-10, )

[0049]

[0050] Compared with the control group, #P<0.05, ##P<0.01; compared with the model group, *P<0.05, **P<0.01.

Claims

1. A composition for lowering uric acid, comprising: (1) an effective amount of celery seed extract; (2) an effective amount of acerola cherry extract; (3) an effective amount of chrysanthemum extract; in, The dosage ratio of celery seed extract, acerola cherry extract and chrysanthemum extract is 10-50:1-5:1-5.

2. The composition according to claim 1, Features: The weight proportion of the celery seed extract is 200-1000 parts, the weight proportion of the acerola cherry extract is 20-100 parts, and the weight proportion of the chrysanthemum extract is 20-100 parts.

3. The composition according to claim 2, Features: The weight proportion of the celery seed extract is 250-1000 parts, the weight proportion of the acerola cherry extract is 24-96 parts, and the weight proportion of the chrysanthemum extract is 25-100 parts.

4. The composition according to claim 3, Features: The weight proportion of the celery seed extract is 250 parts, the weight proportion of the acerola cherry extract is 24 parts, and the weight proportion of the chrysanthemum extract is 25 parts; Or the weight proportion of the celery seed extract is 500 parts, the weight proportion of the acerola cherry extract is 24 parts, and the weight proportion of the chrysanthemum extract is 25 parts; Or the weight proportion of the celery seed extract is 500 parts, the weight proportion of the acerola cherry extract is 48 parts, and the weight proportion of the chrysanthemum extract is 50 parts; Or the weight proportion of the celery seed extract is 750 parts, the weight proportion of the acerola cherry extract is 72 parts, and the weight proportion of the chrysanthemum extract is 75 parts; Or the weight proportion of the celery seed extract is 1000 parts, the weight proportion of the acerola cherry extract is 96 parts, and the weight proportion of the chrysanthemum extract is 100 parts.

5. The composition according to claims 1 to 4, Features: The composition is added with auxiliary materials to prepare oral dosage forms such as common tablets, chewable tablets, soft capsules, hard capsules, powders and granules.

6. Use of the composition according to claims 1 to 5 in the preparation of a product capable of reducing uric acid.

Citation Information

Cited By

  • Application of composition of sour cherry powder and celery seed powder and compound containing composition

    CN122075591A